200
Views
4
CrossRef citations to date
0
Altmetric
Infectious Disease

Adoption in Canada of an international risk scoring tool to predict respiratory syncytial virus hospitalization in moderate-to-late preterm infants

ORCID Icon, , ORCID Icon & ORCID Icon
Pages 1149-1153 | Received 31 Dec 2020, Accepted 29 Mar 2021, Published online: 21 Apr 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Barry S. Rodgers-Gray, John R. Fullarton, Xavier Carbonell-Estrany, Ian P. Keary, Jean-Éric Tarride & Bosco A. Paes. (2023) Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants. Journal of Medical Economics 26:1, pages 630-643.
Read now

Articles from other publishers (3)

Bosco Paes, Marcello Lanari, Barry Rodgers-Gray, John Fullarton & Xavier Carbonell-Estrany. (2024) Opinion: The optimal use of risk factors to guide palivizumab prophylaxis against severe respiratory syncytial virus infection in moderate-to-late preterm infants. Frontiers in Pediatrics 12.
Crossref
Akhil Maheshwari, Srijan Singh, Ilhama Namazova, John T Benjamin & Yuping Wang. (2023) Respiratory Syncytial Virus Infections in Neonates: A Persisting Problem. Newborn 2:3, pages 222-234.
Crossref
Chak Foon Tso, Carson Lam, Jacob Calvert & Qingqing Mao. (2022) Machine learning early prediction of respiratory syncytial virus in pediatric hospitalized patients. Frontiers in Pediatrics 10.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.